title: Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.
abstract: OBJECTIVE
  Hepatitis C virus (HCV) infection is a challenge to prevent and treat because of the rapid development of drug resistance and escape. Viral entry is required for initiation, spread, and maintenance of infection, making it an attractive target for antiviral strategies. The tight junction protein claudin-1 (CLDN1) has been shown to be required for entry of HCV into the cell.
  
  
  METHODS
  Using genetic immunization, we produced 6 monoclonal antibodies against the host entry factor CLDN1. The effects of antibodies on HCV infection were analyzed in human cell lines and primary human hepatocytes.
  
  
  RESULTS
  Competition and binding studies demonstrated that antibodies interacted with conformational epitopes of the first extracellular loop of CLDN1; binding of these antibodies required the motif W(30)-GLW(51)-C(54)-C(64) and residues in the N-terminal third of CLDN1. The monoclonal antibodies against CLDN1 efficiently inhibited infection by HCV of all major genotypes as well as highly variable HCV quasispecies isolated from individual patients. Furthermore, antibodies efficiently blocked cell entry of highly infectious escape variants of HCV that were resistant to neutralizing antibodies.
  
  
  CONCLUSIONS
  Monoclonal antibodies against the HCV entry factor CLDN1 might be used to prevent HCV infection, such as after liver transplantation, and might also restrain virus spread in chronically infected patients.
authors.affiliation: Inserm, U748, Strasbourg, France.
authors.forename: Isabel
authors.initials: I
authors.lastname: Fofana
authors.forename: Sophie E
authors.initials: SE
authors.lastname: Krieger
authors.forename: Fritz
authors.initials: F
authors.lastname: Grunert
authors.forename: Sandra
authors.initials: S
authors.lastname: Glauben
authors.forename: Fei
authors.initials: F
authors.lastname: Xiao
authors.forename: Samira
authors.initials: S
authors.lastname: Fafi-Kremer
authors.forename: Eric
authors.initials: E
authors.lastname: Soulier
authors.forename: Cathy
authors.initials: C
authors.lastname: Royer
authors.forename: Christine
authors.initials: C
authors.lastname: Thumann
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Mee
authors.forename: Jane A
authors.initials: JA
authors.lastname: McKeating
authors.forename: Tatjana
authors.initials: T
authors.lastname: Dragic
authors.forename: Patrick
authors.initials: P
authors.lastname: Pessaux
authors.forename: Francoise
authors.initials: F
authors.lastname: Stoll-Keller
authors.forename: Catherine
authors.initials: C
authors.lastname: Schuster
authors.forename: John
authors.initials: J
authors.lastname: Thompson
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Baumert
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000494:pharmacology* / Q000633:toxicity; D000918:Antibody Specificity; D000998:Antiviral Agents / Q000378:metabolism / Q000494:pharmacology* / Q000633:toxicity; D001666:Binding Sites, Antibody; D001667:Binding, Competitive; D016466:CHO Cells; D002470:Cell Survival / Q000187:drug effects; D062445:Claudin-1; D006224:Cricetinae; D003412:Cricetulus; D004305:Dose-Response Relationship, Drug; D000939:Epitopes; D005838:Genotype; D056945:Hep G2 Cells; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics / Q000472:pathogenicity; D006526:Hepatitis C / Q000276:immunology / Q000517:prevention & control*; D022781:Hepatocytes / Q000187:drug effects* / Q000276:immunology / Q000821:virology; D006801:Humans; D008565:Membrane Proteins / Q000037:antagonists & inhibitors* / Q000276:immunology; D053586:Virus Internalization / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; C568108:CLDN1 protein, human; D062445:Claudin-1; D000939:Epitopes; D008565:Membrane Proteins